Indian health sector is proud of its first native launch super advanced anti-malaria drug. This drug is refered to as "Synriam". Ranbaxy Laboratories has produced this drug and formally introduced it for marketing across the nation. Health Minister Ghulam Nabi Azad has endorsed this drug in the presence of Mr. Vilasrao Deshmukh, Minister of Science and Technology. Synriam has been developed by Ranbaxy Laboratories in association with the Department of Science and Technology. The Indian Council for Medical Research has stretched its support to the cause.
Malaria is a serious health concern in today’s time. It has claimed more than half a million lives each year worldwide. Shockingly, India contributes to 77 per cent of malaria cases out of the 2.5 million cases of malaria has been reported on a yearly basis from South East Asia.
The dual-molecule combination drug conforms to the recommendations of World Health Organisation (WHO) and will be required to be taken only once a day for three days.
The drug Synriam should be used to treat uncomplicated “Plasmodium falciparum†malaria in adults. It also offers significant relief from most of the symptoms associate to malaria including high fever. The best part is that the drug enjoys a high cure rate of more than 95%.
India is now associating with the elite club of various nations for this latest ant-malaria drug facility on the day celebrated as the World Malaria Day. Mr. Azad expressed his desire to make dedicated efforts towards accessibility of this drug widely and in an affordable manner to help poor and needy buy it.
After a dedicated research on the drug in the year 2003, Ranbaxy Laboratories have received the approval of Drug Controller General of India's (DCGI) in 2011 for the manufacture and marketing of the drug in India.